Soreide Law Group is investigating potential claims versus Aegis Capital Corp regarding its sale of Ampio Pharmaceuticals stock to Aegis customers. Aegis was joint booking running manager for Ampio (AMPE) in July 2012 when the company sold additional stock to the public. On the day of the offering the stock traded to a high of 4.25. The stock has trended lower since the sale to the public and is currently trading at .89 per share. Despite years of struggles, Aegis' research department consistently rated the stock as a buy with price projections as high as $15 per share.
If your stock broker recommended AMPE please contact Soreide Law Group for a free legal consultation 1-888-760-6552.
Investors may have suffered financial harm by securities broker David Jay Betman [CRD: 1380281, West Conshohocken, Pennsylvania], based on publicly available information found on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Betman has worked for Morgan Stanley since March 25, 2010, as a securities broker and since March 26, 2010, as a financial advisor. See the […]
Investors potentially experienced sales practice violations by securities broker Andrew Martz [CRD: 5118326, Southlake, Texas], given the disclosures on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Andrew Martz worked for Western International Securities Inc. and Western International Securities from July 13, 2017, and July 14, 2017, respectively, through June 5, 2025, and has been registered with […]
Investors potentially incurred losses because of securities broker Richard Raymond Brown [CRD: 2541545, Valley Village, California], according to public information on Financial Industry Regulatory Authority (FINRA) BrokerCheck. Brown worked for Lincoln Financial Advisors Corporation from December 19, 1997, to December 26, 2019, and has been associated with Arete Wealth Management LLC and Arete Wealth Advisors […]
Phone:
Fax: 1-954-760-6553
Email: info@securitieslawyer.com